US5026687A
(en)
|
1990-01-03 |
1991-06-25 |
The United States Of America As Represented By The Department Of Health And Human Services |
Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
|
EP0627930A4
(fr)
|
1992-07-13 |
1997-08-20 |
Kenneth E Sherman |
Composition et procede de traitement de l'hepatite b.
|
US6107027A
(en)
|
1994-12-14 |
2000-08-22 |
University Of Washington |
Ribozymes for treating hepatitis C
|
GB9505025D0
(en)
|
1995-03-13 |
1995-05-03 |
Medical Res Council |
Chemical compounds
|
US6387365B1
(en)
|
1995-05-19 |
2002-05-14 |
Schering Corporation |
Combination therapy for chronic hepatitis C infection
|
US5980884A
(en)
|
1996-02-05 |
1999-11-09 |
Amgen, Inc. |
Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
|
GB9605293D0
(en)
|
1996-03-13 |
1996-05-15 |
Glaxo Group Ltd |
Medicaments
|
US5922757A
(en)
|
1996-09-30 |
1999-07-13 |
The Regents Of The University Of California |
Treatment and prevention of hepatic disorders
|
WO1998019670A2
(fr)
|
1996-11-01 |
1998-05-14 |
Thomas Najarian |
Procedes et compositions de traitement des infections par le virus de l'hepatite c
|
IL119833A
(en)
|
1996-12-15 |
2001-01-11 |
Lavie David |
Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
|
US6103706A
(en)
|
1997-04-29 |
2000-08-15 |
New York Blood Center, Inc. |
Methods for treating viral infections
|
US6010890A
(en)
|
1997-04-29 |
2000-01-04 |
New York Blood Center, Inc. |
Method for viral inactivation and compositions for use in same
|
US6143752A
(en)
|
1997-08-01 |
2000-11-07 |
Oren; Ran |
Method for preventing or arresting liver damage in humans
|
PT903148E
(pt)
|
1997-09-21 |
2002-02-28 |
Schering Corp |
Terapia de combinacao para a erradicacao de rna de hcv detectavel em doentes tendo infeccao cronica pelo virus da hepatite c
|
EP1023901A4
(fr)
|
1997-10-13 |
2004-10-27 |
Otsuka Pharma Co Ltd |
Produit d'amelioration de l'effet curatif sur l'hepatite c et son application
|
FR2771637B1
(fr)
|
1997-12-01 |
2003-10-24 |
Hutchinson |
Utilisation d'un halogenure de dialkyldialkylammonium par voie parenterale dans les infections bacteriennes et virales
|
EP1037636A4
(fr)
|
1997-12-11 |
2004-08-18 |
Univ Oxford |
Inhibition de la replication virale associee a une membrane cellulaire
|
CA2313049A1
(fr)
|
1997-12-17 |
1999-06-24 |
Cornell Research Foundation, Inc. |
. inhibition de la cyclooxygenase-2
|
US7462605B2
(en)
|
1998-01-23 |
2008-12-09 |
Celmed Oncology (Usa), Inc. |
Phosphoramidate compounds and methods of use
|
WO1999049873A1
(fr)
|
1998-03-27 |
1999-10-07 |
Regents Of The University Of Minnesota |
Nucleosides presentant une activite antivirale et anticancereuse
|
JP2000007578A
(ja)
|
1998-06-24 |
2000-01-11 |
Hiroaki Okushin |
C型肝炎ウイルスの陰性化のための投薬システム
|
JP4350898B2
(ja)
|
1998-07-01 |
2009-10-21 |
デビオファーム・ソシエテ・アノニム |
活性の特徴が改善された新規のシクロスポリン
|
RU2158604C2
(ru)
|
1998-07-03 |
2000-11-10 |
Толоконская Наталья Петровна |
Способ лечения вирусного гепатита c
|
US6323180B1
(en)
|
1998-08-10 |
2001-11-27 |
Boehringer Ingelheim (Canada) Ltd |
Hepatitis C inhibitor tri-peptides
|
US6403564B1
(en)
|
1998-10-16 |
2002-06-11 |
Schering Corporation |
Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
|
CA2346447C
(fr)
|
1998-10-16 |
2006-01-31 |
Schering Corporation |
Therapie combinee ribavirine-interferon alpha permettant de supprimer l'arn de vhc pouvant etre detecte chez des patients atteints de l'hepatite c chronique
|
US20080275005A1
(en)
|
1998-11-25 |
2008-11-06 |
Murphy Michael P |
Mitochondrially targeted antioxidants
|
AR022116A1
(es)
|
1998-12-18 |
2002-09-04 |
Schering Corp |
Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa
|
US6824768B2
(en)
|
1998-12-18 |
2004-11-30 |
Schering Corporation |
Ribavirin-pegylated interferon alfa induction HCV combination therapy
|
AU2157000A
(en)
|
1998-12-18 |
2000-07-12 |
Schering Corporation |
Ribavirin-pegylated interferon alfa induction hcv combination therapy
|
JP2000212099A
(ja)
|
1999-01-19 |
2000-08-02 |
Mochida Pharmaceut Co Ltd |
ウイルス性肝炎治療剤
|
ATE286407T1
(de)
|
1999-02-13 |
2005-01-15 |
Purepulse Technologies Inc |
Verfahren zur inaktivierung von pathogenen mittels breitspektrum-pulslicht
|
GB2355932B
(en)
|
1999-04-12 |
2004-01-07 |
Univ Madras |
A pharmaceutical formulation suitable for the treatment of hepatitis B, hepatitis C and other viral infections of the liver and a process for its preparation
|
US6849254B1
(en)
|
1999-04-19 |
2005-02-01 |
Schering Corporation |
HCV combination therapy
|
DE60042073D1
(de)
|
1999-07-22 |
2009-06-04 |
Celmed Oncology Usa Inc |
Enzym katalisierte therapeutische aktivierung
|
CA2380653A1
(fr)
|
1999-08-13 |
2001-02-22 |
F. Hoffmann-La Roche Ag |
Mofetilmycophenolate associe a peg-ifn-alpha
|
US20050245502A1
(en)
|
1999-08-23 |
2005-11-03 |
Phoenix Biosciences |
Treatments for viral infections
|
KR100392292B1
(ko)
|
2000-01-07 |
2003-07-22 |
주식회사 펩트론 |
5원환 융합 방향족 헤테로사이클릭 화합물을 유효성분으로 하는 hcv 치료제 조성물
|
US6727267B2
(en)
|
2000-04-05 |
2004-04-27 |
Tularik Inc. |
NS5B HVC polymerase inhibitors
|
AU764095B2
(en)
|
2000-04-07 |
2003-08-07 |
Shionogi & Co., Ltd. |
Preincubation assay method
|
ES2373488T3
(es)
|
2000-04-18 |
2012-02-06 |
Virco Bvba |
Métodos para medir la resistencia a los fármacos frente a hcv.
|
US6415797B1
(en)
|
2000-07-07 |
2002-07-09 |
First Circle Medical, Inc. |
Treatment of human herpesviruses using hyperthermia
|
IL153670A0
(en)
|
2000-07-21 |
2003-07-06 |
Schering Corp |
Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
|
US7244721B2
(en)
|
2000-07-21 |
2007-07-17 |
Schering Corporation |
Peptides as NS3-serine protease inhibitors of hepatitis C virus
|
MXPA03001039A
(es)
|
2000-08-02 |
2004-09-10 |
Johnson & Johnson |
Quimioterapia anti-viral y anti-tumor mejorada mediante administracion de eritropoeitina.
|
SV2003000617A
(es)
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
EP1430903A1
(fr)
|
2000-10-12 |
2004-06-23 |
Viromics Gmbh |
Inhibiteurs du proteasome pour le traitement des infections virales
|
CA2462681A1
(fr)
|
2000-10-13 |
2002-04-18 |
Monash University |
Prevention de maladies par reactivation du thymus
|
WO2002032414A2
(fr)
|
2000-10-18 |
2002-04-25 |
Schering Corporation |
Polytherapie a base de ribavirine et d'interferon alpha pegyle contre le virus de l'hepatite c
|
FR2815543B1
(fr)
|
2000-10-19 |
2003-10-24 |
Sedat |
Seringue d'auto-injection d'un melange extemporane
|
WO2002055100A2
(fr)
|
2000-10-20 |
2002-07-18 |
Genetics Institute, Llc |
Procédé et composition pour renforcer une réponse immunitaire
|
JP2004513136A
(ja)
|
2000-11-08 |
2004-04-30 |
スリル バイオメディカル コーポレーション |
抗癌剤として有用な新規ポリアミンアナログ−アミノ酸結合体
|
WO2002053096A2
(fr)
|
2000-12-06 |
2002-07-11 |
The Trustees Of The University Of Pennsylvania |
Monotherapie et polytherapie mettant en oeuvre des medicaments ciblant des proteines cellulaires et des medicaments ciblant des proteines codees par un agent pathogene
|
EP1355916B1
(fr)
|
2001-01-22 |
2007-01-10 |
Merck & Co., Inc. |
Derives de nucleoside servant d'inhibiteurs de l'arn polymerase virale arn dependante
|
US7105499B2
(en)
|
2001-01-22 |
2006-09-12 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
CN1245215C
(zh)
|
2001-02-28 |
2006-03-15 |
四川省生物工程研究中心 |
重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
|
GB0107924D0
(en)
|
2001-03-29 |
2001-05-23 |
Angeletti P Ist Richerche Bio |
Inhibitor of hepatitis C virus NS3 protease
|
US6673775B2
(en)
|
2001-04-18 |
2004-01-06 |
Schering Corporation |
Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
|
AU2002259130A1
(en)
|
2001-05-03 |
2002-11-18 |
Eli Lilly And Company |
Agents for treatment of hcv and methods of use
|
US6833351B2
(en)
|
2001-05-21 |
2004-12-21 |
Douglas T. Dieterich |
Method of treating anemia caused by ribavirin treatment of hepatitis C using erythropoietin alpha
|
WO2003002152A2
(fr)
|
2001-06-29 |
2003-01-09 |
Maxygen Aps |
Formulations d'interféron
|
US20030138403A1
(en)
|
2001-06-29 |
2003-07-24 |
Maxygen Aps |
Interferon formulations
|
CN1549724A
(zh)
|
2001-07-20 |
2004-11-24 |
����ͨѶ�ɷ�����˾ |
治疗肝纤维化的方法
|
WO2003024461A1
(fr)
|
2001-09-20 |
2003-03-27 |
Schering Corporation |
Polytherapie de l'hepatite c
|
KR20040037191A
(ko)
|
2001-09-28 |
2004-05-04 |
인터뮨, 인크. |
치료 실패 환자에서 c형 간염 바이러스 감염의 치료 방법
|
PL369129A1
(en)
|
2001-09-28 |
2005-04-18 |
Intermune, Inc. |
Method for treating hepatitis c virus infection in treatment failure patients
|
CA2460690A1
(fr)
|
2001-10-05 |
2003-04-17 |
Intermune, Inc. |
Procede de traitement de l'infection par le virus de l'hepatite au moyen d'un profil de diffusion d'interferon multiphasique
|
PE20030545A1
(es)
|
2001-10-31 |
2003-06-19 |
Schering Corp |
Formulaciones de jarabe de ribavirina
|
WO2003037908A1
(fr)
|
2001-10-31 |
2003-05-08 |
Ribapharm Inc. |
Therapie de combinaison antivirale et compositions
|
WO2003042377A1
(fr)
|
2001-11-07 |
2003-05-22 |
Kirin Beer Kabushiki Kaisha |
Activation de la proliferation des cellules t in vitro et populations de cellules t ayant prolifere
|
AUPR879601A0
(en)
|
2001-11-09 |
2001-12-06 |
Biota Scientific Management Pty Ltd |
Novel chemical compounds and their use
|
WO2003049760A1
(fr)
|
2001-12-07 |
2003-06-19 |
Intermune, Inc. |
Compositions et procede de traitement de l'infection par le virus de l'hepatite
|
DE60221627D1
(de)
|
2001-12-21 |
2007-09-20 |
Virochem Pharma Inc |
Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren
|
US6906190B2
(en)
|
2002-01-04 |
2005-06-14 |
Ribapharm Inc. |
Inhibitors for de novo-RNA polymerases and methods of identifying targets for same
|
RU2212248C1
(ru)
|
2002-01-21 |
2003-09-20 |
Государственное образовательное учреждение высшего профессионального образования Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова |
Способ лечения больных хроническим вирусным гепатитом c
|
AU2003217747A1
(en)
|
2002-02-26 |
2003-09-09 |
North Shore-Long Island Jewish Research Insitute |
Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
|
CA2383243A1
(fr)
|
2002-04-23 |
2003-10-23 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Methode pour inhiber la fibrogenese
|
MY140680A
(en)
|
2002-05-20 |
2010-01-15 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
AU2003249659A1
(en)
|
2002-05-31 |
2003-12-19 |
Schering Corporation |
Combination therapy for rna virus infections involving ribavirin and impdh inhibitors
|
TWI334785B
(en)
|
2002-06-03 |
2010-12-21 |
Serono Lab |
Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
|
US7608600B2
(en)
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
JP4409430B2
(ja)
|
2002-07-03 |
2010-02-03 |
小野薬品工業株式会社 |
免疫賦活組成物
|
ITMI20021860A1
(it)
|
2002-08-28 |
2004-02-29 |
Scalia Antonio Cassar |
Impiego dei triptani come agenti antivirali.
|
AU2002356422A1
(en)
|
2002-11-01 |
2004-05-25 |
Cadila Healthcare Limited |
Mthod for producing recombinant human interferon alpha 2b polypeptide in pichia pastoris
|
WO2004043435A2
(fr)
|
2002-11-13 |
2004-05-27 |
Control Delivery Systems, Inc. |
Administration systemique d'agents antiviraux
|
AU2003295773A1
(en)
|
2002-11-21 |
2004-06-18 |
Novacea, Inc. |
Treatment of liver disease with active vitamin d compounds
|
EP1596846A2
(fr)
|
2003-02-18 |
2005-11-23 |
Pfizer Inc. |
Inhibiteurs du virus de l'hepatite c, compositions et traitements utilisant ces inhibiteurs
|
WO2004078194A1
(fr)
|
2003-02-28 |
2004-09-16 |
Intermune, Inc. |
Therapie aux interferons pour le traitement de maladies virales et de la fibrose du foie
|
WO2004078127A2
(fr)
|
2003-02-28 |
2004-09-16 |
Intermune, Inc. |
Methode d'administration continue pour traiter les infections provoquees par le virus de l'hepatite
|
WO2005016288A2
(fr)
|
2003-02-28 |
2005-02-24 |
Intermune, Inc. |
Methodes et compositions de traitement de maladies virales
|
TWI269656B
(en)
|
2003-03-05 |
2007-01-01 |
Original Image Co Ltd |
Therapeutical composition for hepatitis C
|
UA64191A
(en)
|
2003-03-14 |
2004-02-16 |
Yevhenii Mykhailovych Neiko |
Method for treating chronic hepatitises of various etiology
|
US20040198840A1
(en)
|
2003-04-02 |
2004-10-07 |
Deloach Reuben Edwin |
Hydrazide substrate safely shuts down disease activated protease to halt viral replication, cancerous cell division, and toxic protein generation
|
ATE422895T1
(de)
|
2003-04-16 |
2009-03-15 |
Bristol Myers Squibb Co |
Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
|
US20040258663A1
(en)
|
2003-05-08 |
2004-12-23 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery of interferon alpha
|
US20050009877A1
(en)
|
2003-05-15 |
2005-01-13 |
Henry Lu |
Methods of identifying HCV NS5B polymerase inhibitors and their uses
|
AU2004240704B9
(en)
|
2003-05-21 |
2009-10-22 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor compounds
|
WO2005003147A2
(fr)
|
2003-05-30 |
2005-01-13 |
Pharmasset, Inc. |
Analogues de nucleosides fluores modifies
|
US20050187170A1
(en)
|
2003-06-16 |
2005-08-25 |
Biocryst Pharmaceuticals, Inc. |
Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
|
EP1643981A2
(fr)
|
2003-06-20 |
2006-04-12 |
Viral Genomix, Inc. |
Compositions antivirales et procedes d'utilisation de ces compositions
|
AU2004260009A1
(en)
|
2003-07-11 |
2005-02-03 |
Oregon Health And Science University |
Methods of treatment and disgnosis using modulators of virus-induced cellular gene sequences
|
MD2549G2
(ro)
|
2003-07-18 |
2005-08-31 |
Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова |
Metodă de tratament a hepatitei virale cronice C.
|
GB0317009D0
(en)
|
2003-07-21 |
2003-08-27 |
Univ Cardiff |
Chemical compounds
|
WO2005018330A1
(fr)
|
2003-08-18 |
2005-03-03 |
Pharmasset, Inc. |
Regime de dosage pour therapie contre flaviviridae
|
OA13310A
(en)
|
2003-09-05 |
2007-04-13 |
Anadys Pharmaceuticals Inc |
TLR7 ligands for the treatment of hepatitis C.
|
US20070110714A1
(en)
|
2003-09-08 |
2007-05-17 |
Norio Hayashi |
Medicinal composition for treatment of chronic hepatitis c
|
AR045870A1
(es)
|
2003-10-11 |
2005-11-16 |
Vertex Pharma |
Terapia de combinacion para la infeccion de virus de hepatitis c
|
CA2540858C
(fr)
|
2003-10-14 |
2009-12-08 |
Intermune, Inc. |
Acylsulfonamides et acides carboxyliques macrocycliques utilises en tant qu'inhibiteurs de la replication du virus de l'hepatite c
|
US7491794B2
(en)
|
2003-10-14 |
2009-02-17 |
Intermune, Inc. |
Macrocyclic compounds as inhibitors of viral replication
|
WO2005038056A1
(fr)
|
2003-10-14 |
2005-04-28 |
Intermune, Inc. |
Polytherapie pour le traitement de maladies virales
|
US20050085528A1
(en)
|
2003-10-17 |
2005-04-21 |
Pfizer Inc. |
Parmaceutical
|
WO2005040816A1
(fr)
|
2003-10-24 |
2005-05-06 |
Immunaid Pty Ltd |
Methode therapeutique
|
RU2006118359A
(ru)
|
2003-10-27 |
2007-12-10 |
Вертекс Фармасьютикалз Инкорпорейтед (Us) |
Комбинации для лечения вирусного гепатита с (hcv)
|
WO2005043118A2
(fr)
|
2003-10-27 |
2005-05-12 |
Vertex Pharmaceuticals Incorporated |
Methode de decouverte de medicament
|
UA68233A
(en)
|
2003-11-25 |
2004-07-15 |
Univ Zaporizhia State Medical |
Method for treating chronic hepatitis c
|
US7078064B2
(en)
|
2003-12-03 |
2006-07-18 |
George Zabrecky |
Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis
|
US20050222198A1
(en)
|
2003-12-22 |
2005-10-06 |
K.U. Leuven Research & Development, Gerhard Puerstinger And Gilead Sciences, Inc. |
Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment
|
WO2005067454A2
(fr)
|
2003-12-23 |
2005-07-28 |
Valeant Pharmaceuticals North America |
Polytherapie pour le traitement de l'infection par le virus de l'hepatite c
|
WO2005062949A2
(fr)
|
2003-12-23 |
2005-07-14 |
Intermune, Inc. |
Methode permettant de traiter l'infection par un hepatovirus
|
WO2005067963A1
(fr)
|
2003-12-23 |
2005-07-28 |
Intermune, Inc. |
Utilisation d'un interferon modifie par du polyethylene glycol dans des schemas posologiques de dosage therapeutique
|
DE10361944A1
(de)
|
2003-12-31 |
2005-07-28 |
Viromics Gmbh |
Mittel zur Hemmung der Virusreplikation durch Regulation der Proteinfaltung
|
US20080234182A1
(en)
|
2007-03-22 |
2008-09-25 |
Innovative Biologics, Inc. |
Blockers of pore-forming virulence factors and their use as anti-infectives
|
EP1718315A4
(fr)
|
2004-02-06 |
2008-08-13 |
Univ Monash |
Utilisation a haute dose et sur un intervalle court de polysaccharides sulfates dans le traitement des infections
|
US7205330B2
(en)
|
2004-02-27 |
2007-04-17 |
Schering Corporation |
Inhibitors of hepatitis C virus NS3 protease
|
KR101312010B1
(ko)
|
2004-04-22 |
2013-09-30 |
하워드 제이 스미스 앤드 어쏘시에이츠 피티와이 엘티디 |
간질환의 지지요법
|
PL1747023T5
(pl)
|
2004-05-04 |
2017-05-31 |
Univ Leland Stanford Junior |
Sposób i kompozycje do zmniejszania ilości genomu wirusowego HCV w komórkach docelowych
|
CA2565658A1
(fr)
|
2004-05-06 |
2005-11-17 |
Conjuchem Biotechnologies Inc. |
Composes pour cible virale specifique
|
AR049635A1
(es)
|
2004-05-06 |
2006-08-23 |
Schering Corp |
(1r,2s,5s)-n-((1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil)-3-((2s)-2-((((1,1-dimetiletil)amino)carbonil)amino)-3,3-dimetil-1-oxobutil)-6,6-dimetil-3-azabiciclo(3.1.0)hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de la hepatitis c
|
WO2006016930A2
(fr)
|
2004-05-14 |
2006-02-16 |
Intermune, Inc. |
Procédés de traitement de l’infection vhc
|
EP1753775B1
(fr)
|
2004-05-25 |
2012-12-26 |
Boehringer Ingelheim International GmbH |
Processus de preparation d'inhibiteurs de protease hcv acyclique
|
KR101370580B1
(ko)
|
2004-06-08 |
2014-03-06 |
버텍스 파마슈티칼스 인코포레이티드 |
약학 조성물
|
KR20070036175A
(ko)
|
2004-07-14 |
2007-04-02 |
노파르티스 아게 |
C형 간염(hcv)의 치료를 위한 시클로스포린과peg화된 인터페론의 조합 제제의 용도
|
CN101023094B
(zh)
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
EP1627641A1
(fr)
|
2004-08-04 |
2006-02-22 |
Victor Eluwa |
Compositions pharmaceutiques comprenant des oxydes de métaux et leurs utilisations
|
US7153848B2
(en)
|
2004-08-09 |
2006-12-26 |
Bristol-Myers Squibb Company |
Inhibitors of HCV replication
|
US7348425B2
(en)
|
2004-08-09 |
2008-03-25 |
Bristol-Myers Squibb Company |
Inhibitors of HCV replication
|
EP1799866A4
(fr)
|
2004-09-27 |
2010-12-01 |
Us Gov Health & Human Serv |
Modulation de l'expression de mxa
|
RU2007116265A
(ru)
|
2004-10-01 |
2008-11-10 |
Вертекс Фармасьютикалз Инкорпорейтед (Us) |
Ингибирование протеазы ns3-ns4a вируса hcv
|
BRPI0515494A
(pt)
|
2004-10-01 |
2008-07-29 |
Debiopharm Sa |
uso de [d-meala] 3-[etval] 4-ciclosporina para o tratamento de infecção por hepatite c e composição farmacêutica compreendendo a referida [d-meala] 3-[etval] 4-ciclosporina
|
US7723310B2
(en)
|
2004-10-18 |
2010-05-25 |
Three Rivers Pharmaceuticals, Llc |
Large dose ribavirin formulations
|
US20060228333A1
(en)
|
2004-10-20 |
2006-10-12 |
Kye-Hyung Paik |
Methods for control of tumors and chronic infections by modulating immunologically informed carriers homing to tolerogenic organs or tissues
|
WO2006043153A2
(fr)
|
2004-10-20 |
2006-04-27 |
Michel Xilinas |
Utilisation de chelateurs d'ions de zinc et de cuivre pour le traitement d'infections causees par des virus vehicules par le sang
|
JP2008517987A
(ja)
|
2004-10-26 |
2008-05-29 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー |
抗ウイルス薬としての四環式インドール誘導体
|
TW201424733A
(zh)
|
2004-10-29 |
2014-07-01 |
Vertex Pharma |
劑量型式
|
US7592315B2
(en)
|
2004-11-02 |
2009-09-22 |
Schering Corporation |
Peptide viral entry inhibitors
|
WO2006055711A1
(fr)
|
2004-11-18 |
2006-05-26 |
Kent Hann |
Composition contenant un isolat d'aloe vera et un prebiotique synergique et leur application therapeutique
|
JP2008523082A
(ja)
|
2004-12-09 |
2008-07-03 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
抗菌活性および抗癌活性を有するヌクレオチド
|
TW200633718A
(en)
|
2004-12-16 |
2006-10-01 |
Applied Research Systems |
Treatment of hepatitis c in the asian population
|
DE102004061746A1
(de)
|
2004-12-22 |
2006-07-06 |
Bayer Healthcare Ag |
Alkinyl-substituierte Thiophene
|
EP1674104A1
(fr)
|
2004-12-24 |
2006-06-28 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Derives d'uridine comme agents antiviraux contre Flavividae, en particulier contre HCV.
|
EP1679065A1
(fr)
|
2005-01-07 |
2006-07-12 |
OctoPlus Sciences B.V. |
Formulation destinée à la libération contrôlée d'interferone par un copolymère bloc PEGT/PBT
|
SG158191A1
(en)
|
2005-01-17 |
2010-01-29 |
Jerini Ag |
C5a receptor antagonists
|
CA2596966A1
(fr)
|
2005-02-03 |
2006-08-10 |
Intarcia Therapeutics, Inc. |
Dispositif osmotique implantable pour l'administration continue de formules en suspension
|
JP2008530124A
(ja)
|
2005-02-09 |
2008-08-07 |
ミジェニックス インコーポレイテッド |
フラビウイルス感染症を処置または予防するための組成物および方法
|
US20060198787A1
(en)
|
2005-02-18 |
2006-09-07 |
Larry Blatt |
Biomarkers for predicting liver fibrosis treatment efficacy
|
WO2006091610A2
(fr)
|
2005-02-23 |
2006-08-31 |
The Brigham And Women's Hospital, Inc. |
Inhibiteurs de l'infectiosite des virus enveloppes
|
US20090156545A1
(en)
|
2005-04-01 |
2009-06-18 |
Hostetler Karl Y |
Substituted Phosphate Esters of Nucleoside Phosphonates
|
US20060229293A1
(en)
|
2005-04-06 |
2006-10-12 |
Addiction Research Institute, Inc. |
Compositions for the treatment of hepatitis C and methods for using compositions for the treatment of hepatitis C
|
EP2842559A3
(fr)
|
2005-04-08 |
2015-03-18 |
Chimerix, Inc. |
Composes, compositions et methodes de traitement d'infections virales et autres troubles medicaux
|
US20060293267A1
(en)
|
2005-04-13 |
2006-12-28 |
University Of Massachusetts |
Dual functional oligonucleotides for use as anti-viral agents
|
US20060241144A1
(en)
|
2005-04-20 |
2006-10-26 |
Albert Cha |
Method for treating apathy syndrome
|
US7569600B2
(en)
|
2005-05-13 |
2009-08-04 |
Virochem Pharma Inc. |
Compounds and methods for the treatment of prevention of Flavivirus infections
|
EP1881828A4
(fr)
|
2005-05-20 |
2009-06-03 |
Valeant Res & Dev |
Traitement de l'hepatite c (hcv) au moyen de doses sous-therapeutiques de ribavirine
|
WO2006127482A1
(fr)
|
2005-05-20 |
2006-11-30 |
Bioenvision, Inc. |
Therapie au bleu de methylene de maladie virale
|
CA2609613A1
(fr)
|
2005-05-26 |
2006-11-30 |
Schering Corporation |
Fusion interferon-igg
|
CA2608709A1
(fr)
|
2005-05-31 |
2006-12-07 |
Novartis Ag |
Traitement des maladies hepatiques dans la pathogenese desquelles le fer joue un role
|
US7793040B2
(en)
|
2005-06-01 |
2010-09-07 |
Microsoft Corporation |
Content addressable memory architecture
|
WO2006130666A2
(fr)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Medicaments et procedes destines a combiner un inhibiteur de protease hcv et un competiteur akr
|
US20060276407A1
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Methods of treating hepatitis C virus
|
US20060276406A1
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Methods of treating hepatitis C virus
|
US20070004635A1
(en)
|
2005-06-02 |
2007-01-04 |
Schering Corporation |
Method of treating interferon non-responders using HCV protease inhibitor
|
US20060275366A1
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Controlled-release formulation
|
WO2006130626A2
(fr)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Procede de modulation de l'activite de la protease du vhc au moyen d'un nouvel inhibiteur de la protease du vhc aux fins de la reduction de la duree du traitement
|
US20070207949A1
(en)
|
2005-06-02 |
2007-09-06 |
Anima Ghosal |
Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
|
EP1891089B1
(fr)
|
2005-06-02 |
2014-11-05 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de protease du VHC en combinaison avec des aliments
|
US20070232527A1
(en)
|
2005-06-02 |
2007-10-04 |
Anima Ghosal |
Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
|
US20070237818A1
(en)
|
2005-06-02 |
2007-10-11 |
Malcolm Bruce A |
Controlled-release formulation of HCV protease inhibitor and methods using the same
|
WO2006130688A2
(fr)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Procedes de dosage asymetrique
|
US20070021351A1
(en)
|
2005-06-02 |
2007-01-25 |
Schering Corporation |
Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
|
EP1919478B1
(fr)
|
2005-06-02 |
2016-03-23 |
Merck Sharp & Dohme Corp. |
Combinaison d'inhibiteurs de protease de vhc et d'un surfactant
|
AU2006255125B2
(en)
|
2005-06-07 |
2011-12-08 |
Yale University |
Methods of treating cancer and other conditions or disease states using LFMAU and LDT
|
RU2293572C1
(ru)
|
2005-07-18 |
2007-02-20 |
Гюнтер Хаазе |
Способ лечения хронического вирусного гепатита с генотип-2 с умеренной активностью
|
US7470664B2
(en)
|
2005-07-20 |
2008-12-30 |
Merck & Co., Inc. |
HCV NS3 protease inhibitors
|
PE20070211A1
(es)
|
2005-07-29 |
2007-05-12 |
Medivir Ab |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
MX2008001528A
(es)
|
2005-08-02 |
2008-04-04 |
Vertex Pharma |
Inhibidores de serina proteasas.
|
AU2006280312A1
(en)
|
2005-08-12 |
2007-02-22 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
DE102005038768A1
(de)
|
2005-08-16 |
2007-02-22 |
Toximed Gmbh |
Pharmazeutischer Wirkstoff gegen Borreliose
|
KR20140069370A
(ko)
|
2005-08-19 |
2014-06-09 |
버텍스 파마슈티칼스 인코포레이티드 |
방법 및 중간체
|
WO2007030560A2
(fr)
|
2005-09-08 |
2007-03-15 |
Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine |
Identification de modulateurs d'un inhibiteur de serine protease de type kazal et leur utilisation comme agents anticancereux et antiviraux
|
US7531164B2
(en)
|
2005-10-21 |
2009-05-12 |
Duke University |
Preventing bacterial or viral infectivity and composition containing infection preventing additive
|
IE20050723A1
(en)
|
2005-10-28 |
2007-05-30 |
Patrick T Prendergast |
Anti-mineralocorticoid therapy of infection
|
WO2007056016A2
(fr)
|
2005-11-02 |
2007-05-18 |
Kemia, Inc. |
Inhibiteurs de cytokine bisamide
|
RU2306134C2
(ru)
|
2005-11-07 |
2007-09-20 |
Государственное образовательное учреждение высшего профессионального образования "Самарский Государственный медицинский университет" |
Способ базисного лечения хронического вирусного гепатита c
|
KR20140098867A
(ko)
|
2005-11-11 |
2014-08-08 |
버텍스 파마슈티칼스 인코포레이티드 |
C형 간염 바이러스 변이체
|
WO2007058384A1
(fr)
|
2005-11-17 |
2007-05-24 |
Osaka University |
Procede d'inhibition de la replication du virus de l'hepatite c, inhibiteur de replication du virus et procede de selection de cet inhibiteur
|
RU2326115C2
(ru)
|
2005-11-21 |
2008-06-10 |
Ефаг АО |
Соли 1-алкиламино-1-дезоксиполиолов с 9-оксоакридин-10-уксусной кислотой, лекарственные препараты на их основе, применение, способы профилактики и лечения
|
AR057623A1
(es)
|
2005-11-28 |
2007-12-05 |
Omega Bio Pharma H K Ltd |
Materiales y metodos para el tratamiento de las infecciones virales
|
US8293726B2
(en)
|
2005-12-02 |
2012-10-23 |
Vianova Labs, Inc. |
Treatment of cancer and other diseases
|
CA2632626C
(fr)
|
2005-12-09 |
2011-10-11 |
F. Hoffmann-La Roche Ag |
Ester de 2'-fluoro-2'-alkyl-2'-desoxycytidines et leur utilisation comme promedicament pour le traitement d'infection par le vhc
|
WO2007075896A2
(fr)
|
2005-12-22 |
2007-07-05 |
Kemia, Inc. |
Inhibiteurs de cytokine heterocycliques
|
RU2306934C1
(ru)
|
2005-12-28 |
2007-09-27 |
ГОУ ВПО Омская Государственная Медицинская Академия |
Способ лечения больных хроническим вирусным гепатитом c
|
ZA200806310B
(en)
|
2006-01-09 |
2009-12-30 |
Romark Lab Lc |
Viral hepatitis treatment
|
MD20060037A
(ro)
|
2006-01-24 |
2007-07-31 |
Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова |
Metodă de tratament al hepatitei virale acute C
|
CA2641859A1
(fr)
|
2006-02-09 |
2007-08-16 |
Schering Corporation |
Combinaisons comprenant un ou plusieurs inhibiteurs de protease du vhc et un ou plusieurs inhibiteurs de polymerase du vhc, et methodes de traitement associees
|
AR059430A1
(es)
|
2006-02-09 |
2008-04-09 |
Schering Corp |
Novedosas combinaciones y metodos de inhibidores del vhc
|
EP1991229A2
(fr)
|
2006-02-27 |
2008-11-19 |
Vertex Pharmaceuticals Incorporated |
Co-cristaux et compositions pharmaceutiques les comprenant
|
BRPI0709567A2
(pt)
|
2006-03-16 |
2011-07-12 |
Vertex Pharma |
inibidores deuterados de protease de hepatite c
|
KR20140107691A
(ko)
|
2006-03-20 |
2014-09-04 |
버텍스 파마슈티칼스 인코포레이티드 |
의약 조성물
|
US20070218138A1
(en)
|
2006-03-20 |
2007-09-20 |
Bittorf Kevin J |
Pharmaceutical Compositions
|
US8895531B2
(en)
|
2006-03-23 |
2014-11-25 |
Rfs Pharma Llc |
2′-fluoronucleoside phosphonates as antiviral agents
|
WO2007111866A2
(fr)
|
2006-03-23 |
2007-10-04 |
Schering Corporation |
Combinaisons d'un ou plusieurs inhibiteurs de la protéase du vhc et d'un ou plusieurs inhibiteurs de cyp3a4, et méthodes de traitement associées
|
WO2007130646A2
(fr)
|
2006-05-04 |
2007-11-15 |
The Rockefeller University |
Co-récepteur de vhc et ses méthodes d'utilisation
|
WO2008060695A2
(fr)
|
2006-05-22 |
2008-05-22 |
The Trustees Of The University Of Pennsylvania |
Inhibition antivirale de la caséine kinase ii
|
DE102006026464A1
(de)
|
2006-06-01 |
2007-12-06 |
Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma |
Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
|
WO2007143164A1
(fr)
|
2006-06-02 |
2007-12-13 |
San Diego State University Research Foundation |
Compositions et procédés pour améliorer l'hyperlipidémie
|
CA2654130A1
(fr)
|
2006-06-04 |
2007-12-13 |
Cellartis Ab |
Nouvelles cellules de type hepatocytes ou de type hepatoblastes derivees de cellules hbs
|
AU2007257959A1
(en)
|
2006-06-09 |
2007-12-21 |
Kemia, Inc. |
Therapy using cytokine inhibitors
|
WO2007149382A2
(fr)
|
2006-06-19 |
2007-12-27 |
The Cleveland Clinic Foundation |
Compositions thérapeutiques et méthodes à utiliser dans le traitement de l'hépatite
|
KR20090024834A
(ko)
|
2006-07-05 |
2009-03-09 |
인터뮨, 인크. |
C형 간염 바이러스 복제의 신규 억제제
|
US20080081791A1
(en)
|
2006-07-06 |
2008-04-03 |
Weida Huang |
Methods of using combinations of siRNAs for treating a disease or a disorder, and for enhancing siRNA efficacy in RNAi
|
JP2009542698A
(ja)
|
2006-07-07 |
2009-12-03 |
ギリアード サイエンシーズ, インコーポレイテッド |
抗ウイルスホスフィナート化合物
|
EA017448B1
(ru)
|
2006-07-13 |
2012-12-28 |
Ачиллион Фармасьютикалз, Инк. |
4-амино-4-оксобутаноиловые пептиды как ингибиторы вирусной репликации
|
WO2008022006A2
(fr)
|
2006-08-11 |
2008-02-21 |
Enanta Pharmaceuticals, Inc. |
Inhibiteurs de protéase du virus de l'hépatite c arylalcoxyle
|
EP1886685A1
(fr)
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Méthodes, utilisations et compositions pour la modulation de la réplication du HCV par activation ou inhibition du récepteur farnesoid X
|
US20100158862A1
(en)
|
2006-08-11 |
2010-06-24 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US8329159B2
(en)
|
2006-08-11 |
2012-12-11 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CA2666814A1
(fr)
|
2006-08-21 |
2008-05-29 |
United Therapeutics Corporation |
Polytherapie destinee a traiter des infections virales
|
WO2008024763A2
(fr)
|
2006-08-25 |
2008-02-28 |
Wyeth |
Identification et caractérisation de variants de réplicons du virus de l'hépatite c présentant une sensibilité réduite à hcv-796, et procédés correspondants
|
TW200815384A
(en)
|
2006-08-25 |
2008-04-01 |
Viropharma Inc |
Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein
|
WO2008073165A2
(fr)
|
2006-08-25 |
2008-06-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
Procédés et compositions permettant d'identifier des agents anti-hcv
|
WO2008032227A2
(fr)
|
2006-09-11 |
2008-03-20 |
Biomas, Ltd. |
Formulations topiques de composés contenant du tellure
|
WO2008033466A2
(fr)
|
2006-09-14 |
2008-03-20 |
Combinatorx (Singapore) Pre. Ltd. |
Compositions et procédés pour le traitement de maladies virales
|
JP2010503396A
(ja)
|
2006-09-14 |
2010-02-04 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
アルブミン融合タンパク質
|
EP2083825A4
(fr)
|
2006-09-26 |
2009-11-04 |
Addiction Res Inst Inc |
Compositions de traitement de l'hépatite c et procédés d'utilisation des compositions de traitement de l'hépatite c
|
RU2421461C2
(ru)
|
2006-10-10 |
2011-06-20 |
Фармассет, Инк. |
Способ получения рибофуранозил-пиримидиновых нуклеозидов
|
US7777395B2
(en)
|
2006-10-12 |
2010-08-17 |
Eastman Kodak Company |
Continuous drop emitter with reduced stimulation crosstalk
|
MX2009004556A
(es)
|
2006-10-27 |
2009-07-10 |
Merck & Co Inc |
Inhibidores de la proteasa ns3 del hcv.
|
AP2579A
(en)
|
2006-11-15 |
2013-01-29 |
Virochem Pharma Inc |
Thiophene analogues for the treatment or prevention of flavivirus infections
|
US20100093824A1
(en)
|
2006-11-29 |
2010-04-15 |
Judith Frydman |
Methods of treating viral infection
|
US20100081672A1
(en)
|
2006-12-07 |
2010-04-01 |
Schering Corporation |
Ph sensitive matrix formulation
|
RU2336096C1
(ru)
|
2006-12-14 |
2008-10-20 |
ООО Медицинский центр "Столица" |
Способ лечения гепатита с
|
RU2345787C2
(ru)
|
2006-12-25 |
2009-02-10 |
Государственное образовательное учреждение высшего профессионального образования "Самарский Государственный медицинский университет" |
Способ лечения хронического вирусного гепатита с
|
US20080261913A1
(en)
|
2006-12-28 |
2008-10-23 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of liver disorders
|
KR20090101372A
(ko)
|
2007-01-08 |
2009-09-25 |
페노믹스 코포레이션 |
매크로시클릭 c형 간염 프로테아제 억제제
|
WO2008089034A2
(fr)
|
2007-01-11 |
2008-07-24 |
Kemia, Inc. |
Inhibiteurs de cytokine
|
US7645732B2
(en)
|
2007-01-24 |
2010-01-12 |
Board Of Regents, The University Of Texas System |
Treating hepatitis C virus infection
|
JP5523110B2
(ja)
|
2007-02-01 |
2014-06-18 |
ヤンセン・アールアンドデイ・アイルランド |
Hcvの大員環状阻害剤の多形形態
|
TWI426918B
(zh)
|
2007-02-12 |
2014-02-21 |
Merck Sharp & Dohme |
Il-23拮抗劑於治療感染之用途
|
DK2125026T3
(en)
|
2007-02-21 |
2014-12-08 |
Allaccem Inc |
FORMATIONS BASED ON bridged POLYCYCLIC COMPOUNDS FOR INHIBITION AND RELIEF OF DISEASES
|
EP2463285A1
(fr)
|
2007-02-27 |
2012-06-13 |
Vertex Pharmaceuticals Inc. |
Co-cristaux et compositions pharmaceutiques les comprenant
|
WO2008106167A1
(fr)
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Polythérapie incluant des inhibiteurs de métalloprotéinases matricielles et des inhibiteurs de caspases pour le traitement de maladies hépatiques
|
MD3477G2
(ro)
|
2007-03-21 |
2008-08-31 |
Николае БОДРУГ |
Metodă de tratament al hepatitei virale cronice C
|
ES2426684T3
(es)
|
2007-03-23 |
2013-10-24 |
To-Bbb Holding B.V. |
Conjugados para el suministro dirigido de fármacos a través de la barrera hematoencefálica
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
WO2008124384A2
(fr)
|
2007-04-03 |
2008-10-16 |
Aegerion Pharmaceuticals, Inc. |
Méthodes de traitement de l'hépatite c
|
JP2010525063A
(ja)
|
2007-04-27 |
2010-07-22 |
キメリクス,インコーポレイテッド |
ヌクレオシドホスホナートが投与された被験者における腎毒性を減少させる方法
|
US20080269205A1
(en)
|
2007-04-27 |
2008-10-30 |
Ondine International, Ltd. |
Methods to prevent vertical transmission of infectious diseases
|
NZ581606A
(en)
|
2007-05-03 |
2012-06-29 |
Intermune Inc |
Novel macrocyclic inhibitors of hepatitis c virus replication
|
CN102872461A
(zh)
|
2007-05-04 |
2013-01-16 |
弗特克斯药品有限公司 |
用于治疗hcv感染的组合治疗
|
AP2009005057A0
(en)
|
2007-05-10 |
2009-12-31 |
Array Biopharma Inc |
Novel peptide inhibitors of hepatitis c virus replication
|
CA2688554A1
(en)
|
2007-05-21 |
2008-11-27 |
Vertex Pharmaceuticals Incorporated |
Dose forms comprising vx-950 and their dosage regimen
|
RU2348412C1
(ru)
|
2007-06-01 |
2009-03-10 |
Лариса Леонидовна Попова |
Способ профилактики рецидива хронического вирусного гепатита с после достижения вирусологической ремиссии
|
WO2008154248A1
(fr)
|
2007-06-06 |
2008-12-18 |
Inova Health System |
Biomarqueurs de l'hépatite c chronique pronostiques
|
MX2009013827A
(es)
|
2007-06-29 |
2010-03-01 |
Gilead Sciences Inc |
Compuestos antivirales.
|
CN100532388C
(zh)
|
2007-07-16 |
2009-08-26 |
郑州大学 |
2’-氟-4’-取代-核苷类似物、其制备方法及应用
|
US8137661B2
(en)
|
2007-07-25 |
2012-03-20 |
Biolex Therapeutics, Inc. |
Controlled release interferon drug products and treatment of HCV infections using same
|
WO2009015389A2
(fr)
|
2007-07-26 |
2009-01-29 |
Entra Pharmaceuticals Inc. |
Systèmes et procédés pour administrer des médicaments
|
WO2009018609A1
(fr)
|
2007-08-03 |
2009-02-12 |
Biotrom Limited |
Compositions et procédés antivirus de l'hépatite c
|
US7728027B2
(en)
|
2007-08-08 |
2010-06-01 |
Bristol-Myers Squibb Company |
Process for synthesizing compounds useful for treating hepatitis C
|
US8629171B2
(en)
|
2007-08-08 |
2014-01-14 |
Bristol-Myers Squibb Company |
Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
|
WO2009026292A1
(fr)
|
2007-08-20 |
2009-02-26 |
Anadys Pharmaceuticals, Inc. |
Procédés de dosage pour le traitement de pathologies
|
MX2010002407A
(es)
|
2007-08-30 |
2010-03-26 |
Vertex Pharma |
Cocristales y composiciones farmaceuticas que los comprenden.
|
WO2009033183A2
(fr)
|
2007-09-08 |
2009-03-12 |
University Of Florida Research Foundation |
Composés et procédés de traitement du virus de l'hépatite c et conditions associées à la liaison cd81
|
US20090076100A1
(en)
|
2007-09-13 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched gsk625433
|
NZ583825A
(en)
|
2007-09-14 |
2012-06-29 |
Schering Corp |
Method of treating hepatitis C patients comprising an HCV protease inhibitor, an antiviral compound and an interferon
|
RU2014147354A
(ru)
*
|
2007-09-17 |
2015-07-10 |
Эббви Бахамаз Лтд. |
Пиримидины, которые могут быть использованы в качестве противоинфекционных средств, и их применения
|
CN102746239B
(zh)
|
2007-09-17 |
2016-02-10 |
艾伯维巴哈马有限公司 |
治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
|
CN101903026B
(zh)
|
2007-09-18 |
2013-05-08 |
斯坦福大学 |
抑制剂在制备用于治疗黄病毒家族病毒感染的药物中的用途
|
US20090082366A1
(en)
|
2007-09-26 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched telaprevir
|
US20090082414A1
(en)
|
2007-09-26 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched viramidine
|
ES2546402T3
(es)
|
2007-10-03 |
2015-09-23 |
Sabell Corporation |
Composiciones a base de hierbas y métodos para tratar trastornos hepáticos
|
US20110270212A1
(en)
|
2007-10-05 |
2011-11-03 |
Medtronic, Inc. |
Pharmacokinetic control for optimized interferon delivery
|
EP2214682A2
(fr)
|
2007-11-05 |
2010-08-11 |
Vertex Pharmaceuticals Incorporated |
Combinaisons thérapeutiques contre hcv comprenant vx-905, peg-ifn et ribavirin
|
PT2219642E
(pt)
|
2007-11-15 |
2011-10-18 |
Madaus Gmbh |
Componente de silibinina para o tratamento de hepatite
|
JP5439384B2
(ja)
|
2007-12-21 |
2014-03-12 |
エフ.ホフマン−ラ ロシュ アーゲー |
大員環の製造方法
|
CA2710144A1
(fr)
|
2007-12-21 |
2009-07-02 |
Avila Therapeutics, Inc. |
Inhibiteurs de hcv protease et leurs utilisations
|
US8202996B2
(en)
*
|
2007-12-21 |
2012-06-19 |
Bristol-Myers Squibb Company |
Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
|
EP2234623A4
(fr)
|
2007-12-27 |
2012-03-28 |
Epiphany Biosciences |
Composés antiviraux
|
US8404659B2
(en)
|
2008-03-07 |
2013-03-26 |
Santaris Pharma A/S |
Pharmaceutical compositions for treatment of MicroRNA related diseases
|
JP5283106B2
(ja)
|
2008-03-14 |
2013-09-04 |
国立大学法人 熊本大学 |
C型肝炎ウイルス阻害剤
|
US20100009970A1
(en)
|
2008-03-19 |
2010-01-14 |
Combinatorx (Singapore) Pte. Ltd. |
Compositions and methods for treatment of viral diseases
|
US20110045001A1
(en)
|
2008-03-28 |
2011-02-24 |
Biontex Laboratories Gmbh |
Transfection results of non-viral gene delivery systems by influencing of the innate immune system
|
US20090257979A1
(en)
|
2008-04-15 |
2009-10-15 |
Intermune, Inc. |
Novel Inhibitors of Hepatitis C Virus Replication
|
EP2280709A1
(fr)
|
2008-04-23 |
2011-02-09 |
Vertex Pharmaceuticals Incorporated |
Traitement d'infections par le virus de l'hépatite c chez des patients non sensibles à un traitement par l'interféron-alpha-2a/2b pegylé et la ribavirine
|
AU2009240630B2
(en)
*
|
2008-04-23 |
2013-07-18 |
Gilead Sciences, Inc. |
Carba-nucleoside analogs for antiviral treatment
|
DE102008029669A1
(de)
|
2008-05-16 |
2009-11-19 |
Schlaak, Jörg Friedrich, Prof. Dr. med. |
Neue Therapeutika für die Hepatitis-Therapie
|
WO2009149179A2
(fr)
|
2008-06-03 |
2009-12-10 |
Aethlon Medical Inc. |
Procédés et dispositifs améliorés de thérapie antivirale
|
CA2727026A1
(fr)
|
2008-06-05 |
2009-12-10 |
Zymogenetics, Llc |
Utilisation d'interferons de type iii pegyles dans le traitement de l'hepatite c
|
WO2009150194A1
(fr)
|
2008-06-10 |
2009-12-17 |
Janssen Pharmaceutica Nv |
Schéma posologique du télaprévir
|
CN102123706B
(zh)
|
2008-06-17 |
2013-08-14 |
米纳斯吉拉斯联合大学 |
血小板活化因子受体在治疗黄病毒科病毒引起的感染中的用途
|
ES2392611T3
(es)
|
2008-07-22 |
2012-12-12 |
Merck Sharp & Dohme Corp. |
Compuestos de quinoxalina macrocíclica como inhibidores de la proteasa NS3 del VHC
|
US20100034839A1
(en)
|
2008-07-25 |
2010-02-11 |
Martha Karen Newell |
Methods for treating viral disorders
|
RU2373952C1
(ru)
|
2008-07-30 |
2009-11-27 |
Юрий Михайлович Амбалов |
Способ лечебного питания больных хроническим гепатитом с, получающих комплексную противовирусную терапию
|
EP2323979A4
(fr)
|
2008-08-06 |
2012-03-07 |
Sciclone Pharmaceuticals Inc |
Traitement ou prévention de l'hépatite c avec composés immunomodulateurs
|
EP2323631A1
(fr)
|
2008-08-07 |
2011-05-25 |
Schering Corporation |
Formulations pharmaceutiques d'un inhibiteur de protéase de vhc dans une dispersion moléculaire solide
|
BRPI0916609A2
(pt)
|
2008-08-07 |
2015-08-04 |
Hoffmann La Roche |
Processo para a preparação de um macrociclo
|
WO2010021681A2
(fr)
|
2008-08-18 |
2010-02-25 |
Combinatorx (Singapore) Pte. Ltd. |
Compositions et procédés pour le traitement de maladies virales
|
WO2010020676A1
(fr)
|
2008-08-20 |
2010-02-25 |
Vib Vzw |
Utilisation d’inhibiteurs de la topoisomérase de type i pour traiter des infections virales
|
CN102307589A
(zh)
|
2008-08-28 |
2012-01-04 |
沃泰克斯药物股份有限公司 |
Hcv的基因型分析
|
EP2351585B1
(fr)
|
2008-08-29 |
2014-03-26 |
Osaka University |
Une composition d' antivirus de l' hépatite c comprenant une acide nucléique contre pa28-gamma
|
EP2323622A1
(fr)
|
2008-09-03 |
2011-05-25 |
Vertex Pharmaceuticals Incorporated |
Co-cristaux et formulations pharmaceutiques les comprenant
|
UY32099A
(es)
|
2008-09-11 |
2010-04-30 |
Enanta Pharm Inc |
Inhibidores macrocíclicos de serina proteasas de hepatitis c
|
MX2011002828A
(es)
|
2008-09-16 |
2011-04-05 |
Boehringer Ingelheim Int |
Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de hcv.
|
WO2010033443A1
(fr)
|
2008-09-17 |
2010-03-25 |
Boehringer Ingelheim International Gmbh |
Polythérapie destinée à traiter une infection par le vhc
|
WO2010031832A2
(fr)
|
2008-09-18 |
2010-03-25 |
Ortho-Mcneil-Janssen Pharmaceuticals, Inc |
Combinaisons synergiques d'un inhibiteur macrocyclique de hcv et d'un dérivé d'acide thiophène-2-carboxylique
|
EP2328656A1
(fr)
|
2008-09-24 |
2011-06-08 |
Vertex Pharmaceuticals Incorporated |
Schéma posologique thérapeutique comprenant peg-interféron, ribavirine et vx-950 pour le traitement d'une hépatite
|
WO2010034670A2
(fr)
|
2008-09-26 |
2010-04-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Kinases de cellules hôtes comme cibles de thérapies antivirales contre l'infection par le virus de l'hépatite c
|
WO2010038796A1
(fr)
|
2008-09-30 |
2010-04-08 |
持田製薬株式会社 |
Agent thérapeutique pour l’hépatite c
|
EP3025727A1
(fr)
|
2008-10-02 |
2016-06-01 |
The J. David Gladstone Institutes |
Procédés de traitement des maladies du foie
|
WO2010042683A1
(fr)
|
2008-10-08 |
2010-04-15 |
The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center |
Traitement de l'infection par le virus de l'hépatite c avec une surexpression de micro-arn-196
|
MX2011004007A
(es)
|
2008-10-15 |
2011-05-19 |
Intermune Inc |
Peptidos antivirales terapeuticos.
|
WO2010049438A2
(fr)
|
2008-10-30 |
2010-05-06 |
Innate Pharma |
Procédés améliorés d’utilisation de phosphoantigènes pour le traitement de maladies
|
WO2010053942A1
(fr)
|
2008-11-05 |
2010-05-14 |
Vertex Pharmaceuticals Incorporated |
Méthodes de traitement d’une infection par le virus de l’hépatite c
|
KR20110087297A
(ko)
|
2008-11-21 |
2011-08-02 |
베링거 인겔하임 인터내셔날 게엠베하 |
경구 투여용의 강력한 hcv 억제제의 약제학적 조성물
|
PL2364309T3
(pl)
|
2008-12-10 |
2015-03-31 |
Achillion Pharmaceuticals Inc |
Nowe peptydy 4-amino-4-oksobutanoilowe jako inhibitory wirusowej replikacji
|
EP2356236B1
(fr)
|
2008-12-11 |
2015-07-29 |
Xiangxue Group (Hong Kong) Company Limited |
Compositions d arnsi et procédés pour inhiber fortement une infection virale
|
SG172227A1
(en)
|
2008-12-18 |
2011-07-28 |
Hoffmann La Roche |
Biomarkers for hcv treatment response
|
US8551973B2
(en)
|
2008-12-23 |
2013-10-08 |
Gilead Pharmasset Llc |
Nucleoside analogs
|
EP2808402A3
(fr)
|
2008-12-29 |
2015-03-25 |
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
Méthodes de prédiction de la réponse au traitement par interférons
|
US8840934B2
(en)
|
2009-01-02 |
2014-09-23 |
Rainbow Pharmaceutical Sa |
Uses of ammonium chloride
|
JP2012514657A
(ja)
*
|
2009-01-09 |
2012-06-28 |
ユニバーシテイ・カレツジ・オブ・カーデイフ・コンサルタンツ・リミテツド |
ウィルス感染を治療するためのグアノシンヌクレオシド化合物のホスホルアミダート誘導体
|
RU2398582C1
(ru)
|
2009-01-19 |
2010-09-10 |
Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.М. Мечникова Федерального агентства по здравоохранению и социальному развитию" |
Способ лечения хронического вирусного гепатита с 1-генотипа с умеренной активностью и репликативностью
|
WO2010093843A2
(fr)
|
2009-02-12 |
2010-08-19 |
Vertex Pharmaceuticals Incorporated |
Polythérapies contre le hcv
|
US8101643B2
(en)
|
2009-02-27 |
2012-01-24 |
Enanta Pharmaceuticals, Inc. |
Benzimidazole derivatives
|
AR075584A1
(es)
|
2009-02-27 |
2011-04-20 |
Intermune Inc |
COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
|
WO2010101649A2
(fr)
|
2009-03-05 |
2010-09-10 |
Pablo Gastaminza |
Inhibition du récepteur sigma 1 en tant que nouvelle approche thérapeutique contre une infection par le virus de l'hépatite c
|
JP2012519666A
(ja)
|
2009-03-05 |
2012-08-30 |
アセンディス ファーマ エーエス |
インターフェロンアルファ担体プロドラッグ
|
ES2599979T3
(es)
|
2009-04-24 |
2017-02-06 |
Roche Innovation Center Copenhagen A/S |
Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
|
WO2010122087A1
(fr)
|
2009-04-25 |
2010-10-28 |
F. Hoffmann-La Roche Ag |
Procédés d'amélioration de pharmacocinétique
|
CA2761258C
(fr)
|
2009-05-13 |
2015-08-04 |
Gilead Sciences, Inc. |
Composes antiviraux
|
TWI576352B
(zh)
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
CN102459647B
(zh)
|
2009-05-21 |
2015-05-06 |
默沙东公司 |
与干扰素-α应答有关的遗传标记
|
CN103819459B
(zh)
*
|
2009-06-11 |
2017-05-17 |
艾伯维巴哈马有限公司 |
抗病毒化合物
|
WO2010151488A1
(fr)
|
2009-06-23 |
2010-12-29 |
Gilead Sciences, Inc. |
Combinaison du bocéprevire avec la 5-({6- [2,4-bis(trifluorométhyl)phényle]pyridazine-3-yl)méthyle)-2-(2-fluorophényle)-5h-imidazo[4,5-c]pyridine pour le traitement du virus de l'hépatite c (vhc)
|
TW201111381A
(en)
|
2009-06-23 |
2011-04-01 |
Gilead Sciences Inc |
Pharmaceutical combinations useful for treating HCV
|
TW201113279A
(en)
|
2009-06-23 |
2011-04-16 |
Gilead Sciences Inc |
Pharmaceutical compositions useful for treating HCV
|
CA2968113C
(fr)
|
2009-06-26 |
2019-05-14 |
Romark Laboratories L.C. |
Composes et procedes pour traiter la grippe
|
PL2451438T3
(pl)
|
2009-07-07 |
2014-07-31 |
Boehringer Ingelheim Int |
Kompozycja farmaceutyczna inhibitora proteazy wirusowego zapalenia wątroby typu C
|
RU2400229C1
(ru)
|
2009-07-13 |
2010-09-27 |
Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" |
СПОСОБ ЛЕЧЕНИЯ БОЛЬНЫХ ХРОНИЧЕСКИМ ВИРУСНЫМ ГЕПАТИТОМ С, ГЕНОТИПОМ 3а
|
EP2467144A1
(fr)
|
2009-07-24 |
2012-06-27 |
ViroLogik GmbH |
Association d'inhibiteurs du protéasome et de médicaments anti-hépatite dans le traitement de l'hépatite
|
EP2459211A1
(fr)
|
2009-07-31 |
2012-06-06 |
Medtronic, Inc. |
Administration continue par voie sous-cutanée d'interféron- à des patients infectés par le virus de l'hépatite c
|
JP2013500713A
(ja)
|
2009-07-31 |
2013-01-10 |
サントル オスピタリエ ウニヴェルシテール ヴォドア |
Hcv感染患者においてc型肝炎の転帰を診断又は予測する方法
|
CN102470158A
(zh)
|
2009-08-27 |
2012-05-23 |
默沙东公司 |
制备丙型肝炎病毒的蛋白酶抑制剂的工艺方法
|
WO2011038224A1
(fr)
|
2009-09-24 |
2011-03-31 |
Trustees Of Boston University |
Procédés pour le traitement de troubles viraux
|
TW201116540A
(en)
|
2009-10-01 |
2011-05-16 |
Intermune Inc |
Therapeutic antiviral peptides
|
US8415374B2
(en)
|
2009-10-12 |
2013-04-09 |
Bristol-Myers Squibb Company |
Combinations of hepatitis C virus inhibitors
|
WO2011056650A2
(fr)
|
2009-10-27 |
2011-05-12 |
Michael Zasloff |
Méthodes et compositions utilisées dans le cadre du traitement et de la prévention d'infections virales
|
WO2011056630A2
(fr)
|
2009-10-27 |
2011-05-12 |
Trustees Of Boston University |
Inhibiteurs du virus de l'hépatite c se présentant sous la forme de petites molécules
|
CN102596201A
(zh)
|
2009-10-30 |
2012-07-18 |
贝林格尔.英格海姆国际有限公司 |
包含BI201335、干扰素α和利巴韦林的HCV组合治疗的用药方案
|
AU2010325065A1
(en)
|
2009-11-09 |
2012-05-24 |
Merck Sharp & Dohme Corp. |
Markers associated with ribavirin-induced anemia
|
WO2011063076A1
(fr)
|
2009-11-19 |
2011-05-26 |
Itherx Pharmaceuticals, Inc. |
Méthodes de traitement du virus de l'hépatite c avec des composés d'oxo-acétamide
|
WO2011066260A2
(fr)
|
2009-11-25 |
2011-06-03 |
Michael Zasloff |
Formulations comprenant des aminostérols
|
US8653070B2
(en)
*
|
2009-12-14 |
2014-02-18 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
CN102753173A
(zh)
|
2009-12-18 |
2012-10-24 |
贝林格尔.英格海姆国际有限公司 |
Hcv组合疗法
|
WO2011079016A1
(fr)
|
2009-12-22 |
2011-06-30 |
Gilead Sciences, Inc. |
Méthodes de traitement d'une infection par le vhb et le vhc
|
CN102905763B
(zh)
|
2009-12-23 |
2015-06-17 |
诺华股份有限公司 |
脂质、脂质组合物和使用它们的方法
|
RU2424794C1
(ru)
|
2009-12-30 |
2011-07-27 |
Государственное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО УГМА Росздрава) |
Способ лечения врожденного гепатита с у детей первого года жизни
|
BR112012018529A2
(pt)
*
|
2010-01-25 |
2016-08-09 |
Enanta Pharm Inc |
inibidores do vírus de hepatite c, sua composição farmacêutica e seu uso, e método para inibição da replicação de um vírus contendo rna
|
RU2012136824A
(ru)
|
2010-01-29 |
2014-03-10 |
Вертекс Фармасьютикалз Инкорпорейтед |
Способы лечения вирусной инфекции гепатита с
|
JP5717768B2
(ja)
*
|
2010-03-10 |
2015-05-13 |
アッヴィ・バハマズ・リミテッド |
固体組成物
|
US8530497B2
(en)
|
2010-03-11 |
2013-09-10 |
Boehringer Ingelheim International Gmbh |
Crystalline salts of a potent HCV inhibitor
|
PT3290428T
(pt)
*
|
2010-03-31 |
2021-12-27 |
Gilead Pharmasset Llc |
Comprimido compreendendo 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2h)-il)¿4¿fluoro¿3¿hidroxi¿4¿metiltetrahidrofuran¿2¿il)metoxi) (fenoxi)fosforil)amino)propanoato de (s)- isopropil cristalino
|
UY33445A
(es)
|
2010-06-10 |
2012-01-31 |
Gilead Sciences Inc |
Un régimen de dosificación, métodos para tratar el virus de la hepatitis c, composición farmacéutica, compuesta, compuestos anti-hcv y kit
|
NZ605440A
(en)
|
2010-06-10 |
2014-05-30 |
Abbvie Bahamas Ltd |
Solid compositions comprising an hcv inhibitor
|
US8592372B2
(en)
|
2010-06-29 |
2013-11-26 |
King Saud University Liver Disease |
Pharmaceutical composition and method of use to improve organ function
|
RU2429877C1
(ru)
|
2010-06-30 |
2011-09-27 |
Общество с ограниченной ответственностью "ИНГИЛС" |
Способ лечения хронического вирусного гепатита с
|
WO2012009503A1
(fr)
|
2010-07-14 |
2012-01-19 |
Vertex Pharmaceuticals Incorporated |
Composition pharmaceutique au goût agréable comprenant vx-950
|
CA2805760A1
(fr)
|
2010-07-30 |
2012-02-02 |
Merck Sharp & Dohme Corp. |
Inhibition du metabolisme du medicament cyp3a
|
US20120196272A1
(en)
|
2010-08-05 |
2012-08-02 |
Roche Molecular Systems, Inc. |
Prediction of HCV Viral Kinetics in Interferon-Free Treatment
|
US20120196794A1
(en)
|
2010-08-06 |
2012-08-02 |
Bristol-Myers Squibb Company |
Combinations of Hepatitis C Virus Inhibitors
|
CN105061534A
(zh)
|
2010-09-22 |
2015-11-18 |
艾丽奥斯生物制药有限公司 |
取代的核苷酸类似物
|
US20130280214A1
(en)
|
2010-09-29 |
2013-10-24 |
Merck Sharp & Dohme Corp. |
Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases
|
MX2013003060A
(es)
|
2010-09-30 |
2013-05-30 |
Boehringer Ingelheim Int |
Terapia de combinacion para tratar infeccion por hcv.
|
KR101594166B1
(ko)
*
|
2010-10-26 |
2016-02-15 |
프레시디오 파마슈티칼스, 인코포레이티드 |
C형 간염 바이러스의 억제제
|
US20120107278A1
(en)
|
2010-10-29 |
2012-05-03 |
Pharmasset, Inc. |
Abbreviated hcv therapy for hcv infected patients with il28b c/c genotype
|
TW201701876A
(zh)
|
2010-12-20 |
2017-01-16 |
吉李德科學股份有限公司 |
治療c型肝炎病毒(hcv)之方法
|
EP2725902A4
(fr)
|
2011-04-06 |
2015-06-24 |
Univ Princeton |
Polythérapie antivirale
|
US20140127159A1
(en)
|
2011-06-23 |
2014-05-08 |
Stella Aps |
HCV Combination Therapy
|
US20140113958A1
(en)
|
2011-06-30 |
2014-04-24 |
Stella Aps |
HCV Combination Therapy
|
JP2014523429A
(ja)
|
2011-06-30 |
2014-09-11 |
ステラ・アンパルトセルスカブ |
Hcv併用療法
|
WO2013024155A1
(fr)
|
2011-08-17 |
2013-02-21 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Combinaisons d'anticorps anti-facteur d'entrée de vhc et d'agents antiviraux à action directe pour le traitement et la prévention de l'infection par le vhc
|
WO2013024158A1
(fr)
|
2011-08-17 |
2013-02-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combinaisons d'inhibiteurs de protéine kinase et d'interférons ou d'inhibiteurs de protéine kinase et d'antiviraux agissant directement pour le traitement et la prévention d'une infection par le vhc
|
WO2013025975A1
(fr)
|
2011-08-17 |
2013-02-21 |
Glaxosmithkline Llc |
Traitements combinés pour l'hépatite c
|
JP2014527061A
(ja)
|
2011-08-24 |
2014-10-09 |
グラクソスミスクライン エルエルシー |
C型肝炎の組合せ治療
|
ME03009B
(fr)
*
|
2011-09-16 |
2018-10-20 |
Gilead Pharmasset Llc |
Procédés permettant de traiter le virus de l'hépatite c (hcv)
|
US8492386B2
(en)
*
|
2011-10-21 |
2013-07-23 |
Abbvie Inc. |
Methods for treating HCV
|
SE1450131A1
(sv)
|
2011-10-21 |
2014-05-07 |
Abbvie Inc |
DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
|
CN104383541A
(zh)
|
2011-10-21 |
2015-03-04 |
艾伯维公司 |
用于治疗hcv的包含至少两种直接抗病毒剂和利巴韦林但无干扰素的方法
|
US8466159B2
(en)
*
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
WO2013066753A1
(fr)
|
2011-10-31 |
2013-05-10 |
Merck Sharp & Dohme Corp. |
Compositions utiles pour le traitement de maladies virales
|
US20130137084A1
(en)
|
2011-11-28 |
2013-05-30 |
Roche Molecular Systems, Inc. |
Single Nucleotide Polymorphism on Chromosome 15 That Predicts HCV Treatment Responses
|
AU2012358804B2
(en)
|
2011-12-22 |
2018-04-19 |
Alios Biopharma, Inc. |
Substituted phosphorothioate nucleotide analogs
|